# APG-115 in Patients With Advanced Solid Tumors or Lymphomas

> **NCT02935907** · PHASE1 · COMPLETED · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 50 (actual)

## Conditions studied

- Patients With Advanced Solid Tumor or Lymphoma

## Interventions

- **DRUG:** APG-115

## Key facts

- **NCT ID:** NCT02935907
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935907, "APG-115 in Patients With Advanced Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02935907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*